Last update Aug. 18, 2021

Favipiravir

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Favipiravir is a viral RNA polymerase inhibitor that has been tested to treat influenza A and B viruses, Ebola, Lassa, and coronavirus 2019-nCoV (Joshi 2021, Shiraki 2020).
Oral administration twice a day for 5 days.

At the date of the last update, the authors did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (low molecular weight and low protein binding) make it likely to pass to milk in an amount that could be significant, although the moderately high volume of distribution and high pKa would make it difficult.

Its possible side effects are diarrhea, decreased neutrophils, and elevated transaminases and uric acid (Taisho 2014).

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.


See below the information of these related products:

Alternatives

We do not have alternatives for Favipiravir.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Favipiravir in other languages or writings:

Group

Favipiravir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Favipiravir in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 98 %
Molecular weight 157 daltons
Protein Binding 54 %
VD 0,29 l/Kg
pKa 9,39 -
Tmax 0,5 - 1,5 hours
T1/2 5,6 ± 2,3 hours

References

  1. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021 Jan;102:501-508. Abstract
  2. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512. Abstract
  3. Taisho. Favipavir (Avigan). Drug Summary. 2014 Full text (link to original source) Full text (in our servers)

Total visits

9,003

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM